MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

SCYNEXIS Company Profile (NASDAQ:SCYX)

Consensus Ratings for SCYNEXIS (NASDAQ:SCYX) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.60 (546.02% upside)

Analysts' Ratings History for SCYNEXIS (NASDAQ:SCYX)
Show:
DateFirmActionRatingPrice TargetActions
6/9/2016Needham & Company LLCReiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Brean CapitalReiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/4/2016WBB SecuritiesInitiated CoverageBuy$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/16/2015RBC CapitalLower Price TargetOutperform$18.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for SCYNEXIS (NASDAQ:SCYX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/17/2016        
5/9/2016Q116($0.63)($0.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2015Q315($0.62)($0.60)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2015Q115($0.43)($0.75)$4.20 million$2.31 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/30/2015($0.71)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.53)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for SCYNEXIS (NASDAQ:SCYX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for SCYNEXIS (NASDAQ:SCYX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for SCYNEXIS (NASDAQ:SCYX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/24/2016Eric FrancoisCFOBuy15,000$2.39$35,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2016Guy MacdonaldDirectorBuy40,000$2.39$95,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2016Marco TagliettiCEOBuy100,000$2.39$239,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/25/2016Ann HanhamDirectorBuy4,225$3.64$15,379.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/25/2016Marco TagliettiCEOBuy5,754$3.26$18,758.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Marco TagliettiCEOBuy5,500$3.37$18,535.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2016Marco TagliettiCEOBuy7,500$3.14$23,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2016Marco TagliettiCEOBuy6,000$3.07$18,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Marco TagliettiCEOBuy22,733$6.79$154,357.07View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015Marco TagliettiCEOBuy25,000$7.82$195,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Marco TagliettiCEOBuy2,267$7.08$16,050.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2015Marco TagliettiCEOBuy50,000$7.07$353,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2014Jean-Yves NothiasDirectorBuy50,000$10.00$500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2014Ventech Capital IiMajor ShareholderBuy28,000$10.00$280,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for SCYNEXIS (NASDAQ:SCYX)
DateHeadline
06/29/16 06:14 PMScynexis Inc (SCYX) CEO Marco Taglietti Bought $239000 of Stocks - GuruFocus.com
06/29/16 08:42 AMBuying Spree of Ambac Financial Group Inc. (AMBC)’s CEO Continues, Plus Noteworthy Insider Buying Activity at Two Other Companies -
06/28/16 06:13 PMScynexis Inc (SCYX) CEO Marco Taglietti Bought $239,000 of Stocks
06/25/16 10:00 AMShare Volatility Check for: SCYNEXIS, Inc. (NASDAQ:SCYX) - Press Telegraph
06/23/16 06:57 PMScynexis Inc (NASDAQ:SCYX) Sinks a Bit Following a Dilution-Inducing Move
06/23/16 08:57 AMScynexis Inc (NASDAQ:SCYX) Sinks a Bit Following a Dilution-Inducing Move - HotStocked
06/22/16 06:16 PMSCYNEXIS, Inc. (SCYX) Updated Price Targets - FTSE News
06/22/16 11:01 AMSCYNEXIS : Announces Launch of Public Offering of Common Stock and Warrants
06/22/16 11:01 AMScynexis (SCYX) Prices $22.5M Common Stock, Warrants Offering
06/21/16 05:49 PMToday's Stocks: SCYNEXIS, Inc. (NASDAQ:SCYX), ITI Inc (NASDAQ:ITCI), O'Reilly Automotive Inc. (NASDAQ:ORLY ... - KC Register
06/21/16 10:38 AMStocks Swings: SCYNEXIS, Inc. (NASDAQ:SCYX), Johnson & Johnson (NYSE:JNJ), Ocean Bio-Chem Inc. (NASDAQ ... - KC Register
06/21/16 10:38 AMAnalyst Views For The Week Ahead: SCYNEXIS, Inc. (SCYX) - Fiscal Standard
06/21/16 08:39 AMSCYNEXIS Announces Pricing of $22.5 Million Public Offering of Common Stock and Warrants - [at noodls] - JERSEY CITY, N.J., June 21, 2016 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of 9,375,000 shares of its common stock and warrants to ...
06/20/16 06:00 PMAfter-Hours Stock Movers 06/20: (IMPV) (NWY) (OPK) Higher; (SCYT) (WERN) (SWFT) Lower (more...)
06/20/16 03:09 PMSCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants - [at noodls] - JERSEY CITY, N.J., June 20, 2016 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase ...
06/20/16 07:00 AMSCYNEXIS Inc. Presents New Clinical and Non-Clinical Data Confirming the Potential of SCY-078 as a Novel Treatment for Life-threatening Fungal Infections - [GlobeNewswire] - SCY-078 shown to be the first glucan synthase inhibitor with high oral bioavailability in humans Fungicidal activity of SCY-078 demonstrated against multiple Candida species, including difficult-to-treat ...
06/15/16 06:12 PMSCYNEXIS, Inc. (NASDAQ:SCYX) Tumbled -9.03%: Bristol-Myers Squibb Company (NYSE:BMY), ONEOK Partners ... - KC Register
06/10/16 09:20 AMYesterday Trading Recap: Juno Therapeutics, Inc. (NASDAQ:JUNO) , SCYNEXIS, Inc. (NASDAQ:SCYX) - Street Updates
06/10/16 08:19 AMSCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at ASM Microbe 2016 - [at noodls] - JERSEY CITY, N.J., June 10, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that results of one Phase 1 study and one nonclinical study of the company's lead ...
06/09/16 06:48 PMAnalysts Offer Insights on Healthcare Companies: SCYNEXIS Inc (NASDAQ: SCYX), Opexa Therapeutics (NASDAQ ... - Analyst Ratings
06/08/16 06:50 PMScynexis (SCYX) Issues Positive Update on Oral SCY-078 Phase 2 vs. Current Standard of Care
06/08/16 03:18 PMSCYNEXIS, Inc. Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors - [at noodls] - Confirmation of Clinically Relevant Antifungal Activity of SCY-078 in Patients with Candida Infections Company to Host a Conference Call Today at 5:00pm ET to Discuss Results JERSEY CITY, N.J., June 08, ...
06/07/16 03:27 PMSCYNEXIS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/17/16 12:24 PMSCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/13/16 09:03 AMSCYNEXIS Gets Orphan Drug Status For SCY-078 -
05/13/16 08:58 AMSCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Candida Infections - [at noodls] - JERSEY CITY, N.J., May 13, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation ...
05/09/16 08:48 AMSCYNEXIS, Inc. Reports First Quarter 2016 Financial Results and Provides Company Update - [at noodls] - JERSEY CITY, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the quarter ended March 31, 2016, and provided an update on ...
05/09/16 08:30 AMScynexis reports 1Q loss -
04/19/16 08:36 AMSCYNEXIS Receives Designation as a Small and Medium Enterprise by the European Medicines Agency - [at noodls] - JERSEY CITY, N.J., April 19, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that the Company has been granted Small and Medium Sized Enterprise (SME) status ...
04/15/16 08:33 AMSCYNEXIS Presents Data Supporting the Activity of its Lead Antifungal Drug Candidate SCY-078 Against Antifungal-resistant Candida Strains at the 13th ASM Conference on Candida and Candidiasis - [at noodls] - JERSEY CITY, N.J., April 15, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that results of three nonclinical studies of the company's lead clinical drug ...
04/11/16 03:58 PMSCYNEXIS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
03/14/16 09:55 AMSCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q4, 2015 By the Numbers -
03/07/16 07:37 AMSCYNEXIS, Inc. Reports Full Year 2015 Financial Results and Provides Company Update - [GlobeNewswire] - JERSEY CITY, N.J., March 07, 2016-- Drug development company SCYNEXIS, Inc. today reported financial results for the year ended December 31, 2015, and provided an update on recent operational and clinical ...
03/07/16 06:52 AMSCYNEXIS INC Files SEC form 10-K, Annual Report -
02/29/16 04:30 PMSCYNEXIS, Inc. to Present at the Cowen and Company 36th Annual Health Care Conference - [GlobeNewswire] - JERSEY CITY, N.J., Feb. 29, 2016-- Drug development company SCYNEXIS, Inc. today announced that the Company will present at the Cowen and Company 36 th Annual Health Care Conference at the Boston Marriott ...
02/03/16 08:05 AMSCYNEXIS, Inc. to Present at Upcoming Investor Conferences - [GlobeNewswire] - JERSEY CITY, N.J., Feb. 03, 2016-- Drug development company SCYNEXIS, Inc. today announced that the Company will present at the following upcoming investor conferences in February:. Leerink Partners 5 ...
01/29/16 11:41 AMScynexis' (SCYX) SCY-078 Receives FDA Fast Track and QIDP Designations - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Drug development company SCYNEXIS, Inc. (Nasdaq: SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track and Qualified ...
01/28/16 11:30 AMSCYNEXIS, Inc. Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 - JERSEY CITY, N.J., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track and Qualified Infectious Disease Product (QIDP ...
01/28/16 10:57 AMSCYNEXIS, Inc. Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections - [at noodls] - JERSEY CITY, N.J., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track and Qualified ...
01/28/16 08:13 AM9:13 am Scynexis: FDA has granted both Fast Track and QIDP designations for the IV formulation of SCY-078, co's novel antifungal product -
01/06/16 03:42 PMSCYNEXIS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
01/04/16 04:29 AMSCYNEXIS Inc (NASDAQ:SCYX) Given Consensus Recommendation of “Buy” by Analysts - Shares of SCYNEXIS Inc (NASDAQ:SCYX) have been given an average broker rating score of 2.00 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a buy rating.
12/29/15 07:05 AMCoverage initiated on Scynexis by WBB Securities -
12/21/15 11:24 AMSCYNEXIS, Inc. Earnings Analysis: Q3, 2015 By the Numbers -
12/08/15 12:17 PMSCYNEXIS INC Financials -
12/01/15 04:27 PMSCYNEXIS, Inc. Initiates Enrollment of the Phase 2 Study of SCY-078 in Vulvovaginal Candidiasis - [at noodls] - JERSEY CITY, N.J., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has initiated enrollment and the first group of patients have been dosed ...
11/27/15 05:30 AMHere is What Hedge Funds Think About SCYNEXIS Inc (SCYX) -
11/24/15 01:31 PMIs Intevac, Inc. (IVAC) A Good Stock To Buy? -
11/13/15 08:16 AMSCYNEXIS, Inc. Reports Third Quarter 2015 Financial Results and Provides Company Update - [at noodls] - JERSEY CITY, N.J., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the quarter ended September 30, 2015, and provided an update ...
11/13/15 08:11 AMScynexis reports 3Q loss -
About SCYNEXIS

SCYNEXIS logoSCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SCYX
  • CUSIP:
Key Metrics:
  • Previous Close: $2.26
  • 50 Day Moving Average: $3.17
  • 200 Day Moving Average: $4.34
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $31.43M
  • Current Quarter EPS Consensus Estimate: $-2.27 EPS
Additional Links:
SCYNEXIS (NASDAQ:SCYX) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha